Welcome to our dedicated page for Akebia Therapeut SEC filings (Ticker: AKBA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Akebia Therapeutics, Inc. (Nasdaq: AKBA) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, offering investors structured access to its official communications. As a biopharmaceutical company focused on kidney disease, Akebia uses filings such as Forms 8-K, 10-K, and 10-Q to report material agreements, financial performance, and key clinical and regulatory developments related to products like Vafseo (vadadustat) and Auryxia (ferric citrate), as well as its rare kidney disease pipeline.
Recent 8-K filings illustrate the type of information investors can expect. One filing describes an amendment to Akebia’s License Agreement with MEDICE Arzneimittel Putter GmbH & Co. KG, under which Akebia supplies vadadustat drug substance and Medice has rights to manufacture Vafseo tablets for Europe and certain other countries, with resulting know-how and patent rights owned by Akebia. Other 8-Ks furnish quarterly financial results, highlight business updates such as Vafseo commercialization metrics, and disclose regulatory decisions, including Akebia’s announcement that it does not plan to initiate the VALOR trial and does not expect to pursue a broad label for Vafseo in CKD patients not on dialysis.
Through this page, users can review annual reports on Form 10-K for comprehensive discussions of risk factors, product portfolios, and strategy; quarterly reports on Form 10-Q for interim financial and operational updates; and current reports on Form 8-K for material events. Insider transaction reports on Form 4, when available, provide visibility into equity transactions by directors and officers. Stock Titan enhances these filings with AI-powered summaries that explain key points, highlight material changes, and help readers quickly understand how new disclosures may relate to Akebia’s kidney disease programs and overall business.